C-Bond Systems Expands Exclusive Distribution Agreement with Quip Laboratories to Include Vimoba Tablets, Approved for Use Against SARS-CoV-2

C-Bond also receives follow-on purchase order in excess of $10K from customer in Philippines for Vimoba Tablets to help combat the spread of COVID-19

Houston, Texas, UNITED STATES


HOUSTON, Feb. 17, 2022 (GLOBE NEWSWIRE) -- C-Bond Systems, Inc. (“C-Bond” or “Company”) (OTC: CBNT), a nanotechnology solutions company, announced today that it has expanded its exclusive distribution agreement with Quip Laboratories, Inc. to include not only MB-10 Tablets but also Vimoba Tablets to help combat the spread of COVID-19 in the markets C-Bond serves. Both MB-10 Tablets and Vimoba Tablets are on EPA’s List N, a list of the products that the EPA has deemed efficacious against SARS-CoV-2, the virus that causes COVID-19. The Company has also received a follow-on order in excess of $10K from a customer in the Philippines to purchase Vimoba Tablets.

Vimoba Tablets are non-corrosive, chlorine dioxide producing tablets that maintain the exact same efficacy, EPA Label claims, dilution rates, and contact times as MB-10 Tablets. Vimoba Tablets also include a buffering agent that makes the Vimoba solution completely non-corrosive on stainless steel, even after prolonged use or exposure and even when the solution dries on the surface.

The companies have also amended the distribution agreement to extend the term for another year, through May 20, 2023. C-Bond has exclusive distribution rights to sell MB-10 and Vimoba in the transportation sector, which includes automotive, trucking, mass transit, dealerships, service providers, and more.

“We are pleased to expand the breadth of our distribution agreement with Quip, a company that has been a great partner to us, to offer customers a wider range of disinfectants to help in the fight against COVID-19,” said Scott R. Silverman, Chairman and CEO of C-Bond.

MB-10 tablets are registered as a broad-spectrum hospital disinfectant that is effective against a wide range of bacteria and viruses, and are safe for hard, non-porous surfaces such as glass, plastics, sealed fiberglass, and a wide range of metals, without leaving residues or odor. MB-10 Tablets also protect without staining or discoloring.

According to the EPA, List N is a list of products that EPA expects will kill all strains and variants of the coronavirus SARS-CoV-2, the virus that causes COVID-19, when used according to the label directions.

About Quip Laboratories
From Environmental Monitoring and Decontamination services, to proprietary disinfectants and sterilants, Quip Laboratories focuses on providing facility hygiene solutions to a variety of industries. With in-house research and development, pathogen identification, production, quality control and sales teams, Quip Laboratories provides a comprehensive approach to efficient and eco-gentle facility hygiene. You can find Quip Labs on the web at www.quiplabs.com or call us today at 1-800-424-2436.

About C-Bond                
C-Bond Systems, Inc. (OTC: CBNT) is a Houston-based nanotechnology company and marketer of the patented and patent-pending C-Bond technology, which is independently proven to strengthen glass in automotive and structural applications. The Company’s Transportation Solutions Group sells C-Bond nanoShield, a liquid solution that strengthens automotive windshields, primarily through distributors. The Company’s Patriot Glass Solutions sells ballistic-resistant glass solutions and forced entry deterrent solutions to private enterprises, schools, and government agencies, primarily through its majority-owned subsidiary, A1 Glass Coating. The Company also sells MB-10 Tablets and Vimoba Tablets, disinfection products on EPA’s List N. For more information, please visit our website: www.cbondsystems.com, Facebook: https://www.facebook.com/cbondsys/ and Twitter: https://twitter.com/CBondSys.

Forward-Looking Statements
Statements in this press release about our future expectations constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company’s ability to successfully commercialize its products; the effect of the COVID-19 global pandemic on the Company’s and its customers’ ability to operate; the Company’s and its customers’ ability to source materials; the Company’s ability to raise capital; potential channel conflicts; as well as other risks. Additional information about these and other factors may be described in the Company’s filings with the Securities and Exchange Commission (“SEC”) including its Form 10-K filed on April 14, 2021, its Forms 10-Q filed on November 15, 2021, August 16, 2021, and May 14, 2021, and in future filings with the SEC. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

 

Contact Data